Related Experiment Video
Updated: Feb 19, 2026
02:08
Surgical Bone Implantation Technique for Rat Tibia Models of Diabetes and Osteoporosis
Published on: July 5, 2024
1.5K
[Antidiabetic drugs and their effect on bone].
Vnitrni Lekarstvi
|November 10, 2017
Summary
Diabetes medications can impact bone health, increasing osteoporosis and fracture risk. This review examines antidiabetic drugs
Area of Science:
- Endocrinology
- Metabolic Diseases
- Bone Biology
Background:
- Diabetes mellitus and osteoporosis are prevalent conditions with significant health impacts.
- Diabetic patients face an elevated risk of bone fractures.
- Antidiabetic medications, while essential, may influence bone metabolism and fracture risk.
Purpose of the Study:
- To review the effects of various antidiabetic treatments on bone health, including bone mineral density, fracture incidence, and bone turnover markers.
- To provide guidance on managing bone health in diabetic patients, considering medication-induced risks.
Main Methods:
- Literature review of studies investigating the relationship between antidiabetic drugs and bone health.
- Analysis of clinical trial data and observational studies.
- Synthesis of findings on specific drug classes like thiazolidinediones, sulfonylureas, incretins, and SGLT2 inhibitors.
Main Results:
- Certain antidiabetic drugs, notably thiazolidinediones, are associated with an increased fracture risk, particularly in women.
- Sulfonylureas may also exert negative effects on bone health.
- Emerging drug classes like incretins and SGLT2 inhibitors are being evaluated for their impact on fracture outcomes.
Conclusions:
- The influence of antidiabetic medications on bone metabolism and fracture risk is a critical consideration in diabetes management.
- A strategic approach is needed to balance glycemic control with the preservation of bone health in diabetic patients.
- Further research is warranted to fully elucidate the long-term skeletal effects of newer antidiabetic agents.
More Related Videos
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
698
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
698
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
615
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
615
01:30Drug toxicity: Drug–Drug Interaction
38
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
38
01:06Oral Hypoglycemic Agents: Glinides
707
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
707
01:23Dipeptidyl Peptidase 4 Inhibitors
734
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
734
01:21Drug Distribution: Tissue Binding
4.1K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
4.1K